Clinical trials: Central Obesity
Abdominal Obesity
A Study to Evaluate Safety, Tolerability of Subcutaneous Injection in Adult Subjects Undergoing Abdominoplasty
Dose-ranging, randomized, double-blind, vehicle-controlled study
- Trial name
- NCT05422378
- Testing
- STP705
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sirnaomics
Hypertension, Abdominal Obesity
Effects of Aliskiren and Amlodipine on the Renin-Angiotensin System (RAS) and Lipid/Carbohydrate Metabolism in Obese Patients With Hypertension
Part 1 determined: aliskiren, amlodipine and angiotensin II concentrations in interstitial fluid of fat and skeletal muscle; aliskiren and angiotensin II concentrations, and renin activity and concentration in fat and skeletal…
- Trial name
- NCT00498433
- Testing
- Aliskiren, Amlodipine
- Where
- 2 sites in Germany
- Volunteers
- 46 people
- Sponsor
- Novartis
Overweight or Obesity
Multicenter Trial Investigating Performance and Safety of the Medical Device SiPore21®
The present clinical investigation is a randomized, double-blinded, placebo-controlled, multicenter international trial, planned to be conducted in Poland, Romania and Slovakia.
- Trial name
- SHINE (NCT06087822)
- Testing
- IMD SiPore21®
- Where
- 27 sites in Poland, Romania and 1 more
- Volunteers
- 318 people
- Sponsor
- Sigrid Therapeutics AB
Abdominal Obesity, Type 2 Diabetes
ORAL ANTIDIABETICS EFFECT ON VISCERAL FAT
Weight control is an essential part of treatment for type 2 diabetes (T2D) patients. Weight loss is associated with decreased haemoglobin A1c (A1c) levels.
- Trial name
- NCT05032001
- Testing
- Biguanide, DPP4 inhibitors, SGLT2 inhibitors
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Metabolic Research Unit
Obesity
Safety and Performance of the CAVU Medical, Inc. Attune Tubing Study
The objectives of this clinical research project are to demonstrate the safety and feasibility of CAVU Medical, Inc.'s Attune Device.
- Trial name
- NCT01422941
- Testing
- CAVU Attune Device
- Where
- 2 sites in Australia
- Volunteers
- 40 people
- Sponsor
- Cavu Medical, Inc.
Obesity
A 1-Year Study of an Investigational Drug in Obese Patients (0557-012)(COMPLETED)
This is a 1-year study to assess the safety, tolerability, and efficacy of an investigational drug in obese patients after a very low calorie diet.
- Trial name
- NCT00092872
- Testing
- MK0557
- Volunteers
- 359 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, Obesity
Study for Pre-Surgical Weight Loss in Type II Diabetes Patients
The purpose of this study is to determine whether the GI Sleeve is safe and effective in treating Type II diabetes patients
- Trial name
- NCT00791128
- Testing
- GI Liner
- Where
- Brazil
- Volunteers
- 22 people
- Sponsor
- Morphic Medical Inc.
Bardet Biedl Syndrome (BBS), Alström Syndrome (AS)
Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe Obesity
This pivotal, phase 3 study is designed to confirm the efficacy and safety of setmelanotide, a potent melanocortin receptor type 4 (MC4R) agonist, for the treatment of obesity and hyperphagia in participants with Bardet Biedl…
- Trial name
- NCT03746522
- Testing
- Setmelanotide
- Where
- 12 sites in United States, Canada and 4 more
- Volunteers
- 52 people
- Sponsor
- Rhythm Pharmaceuticals, Inc.
Diabetes Mellitus and Heart Failure
A Dose Finding Study to Assess the Effect of LIK066 Compared to Placebo or Empagliflozin in Patients With Type 2 Diabetes Mellitus and Heart Failure
This was a dose-finding study to evaluate the efficacy, safety and tolerability of 3 different doses of LIK066 compared to placebo or empagliflozin in T2DM patients with heart failure
- Trial name
- NCT03152552
- Testing
- LIK066, Empagliflozin
- Where
- 106 sites in United States, Argentina and 22 more
- Volunteers
- 125 people
- Sponsor
- Novartis Pharmaceuticals
Non Invasive Body Contouring
Clinical Evaluation of Linear Z for Body Contouring
This clinical study will evaluate the safety and effectiveness of LinearZ, a non-invasive focused ultrasound device, for body contouring of the lower abdomen and flanks.
- Trial name
- NCT07802431
- Testing
- High Intensity Focused Ultrasound
- Where
- Mexico
- Volunteers
- 30 people
- Sponsor
- Jeisys Medical Inc
Obesity
Japanese Study of Rimonabant in Obese Patients With Dyslipidemia (VENUS)
The primary objective of this study is to assess the efficacy of SR141716 compared to placebo on body weight and triglycerides changes over a period of 52 weeks.
- Trial name
- NCT00434096
- Testing
- rimonabant (SR141716)
- Where
- Japan
- Volunteers
- 915 people
- Sponsor
- Sanofi
Overweight, Obesity
Safety and Performance Evaluation of the Epitomee Device for Enhancing Satiety and Weight Loss.
Study design to demonstrate the safety and performance of the Epitomee Device
- Trial name
- NCT03610958
- Testing
- Epitomee Device
- Where
- Israel
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Epitomee medical
Obesity
Feasibility Trial of ValenTx Endo Bypass System
The purpose of the study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese patients.
- Trial name
- NCT01207804
- Testing
- ValenTx Endo Bypass System
- Where
- Mexico
- Volunteers
- 12 people
- Sponsor
- ValenTx, Inc.
Obesity
Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight Loss
Multiple pathways including peripheral and central hormones and neurotransmitters are involved in the regulation of food intake and body weight. One of the most studied pathways involves the melanocortin receptor.
- Trial name
- NCT00779519
- Testing
- TTP435
- Where
- 12 sites in United States, Canada
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- vTv Therapeutics
Obesity
Zonisamide SR Plus Bupropion SR Combination Therapy in Subjects With Obesity
The purpose of this study is determine if the combination of zonisamide SR and bupropion SR are is more effective than either drug given alone or placebo in the treatment of obesity.
- Trial name
- NCT00709371
- Testing
- Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day
- Where
- 20 sites in United States
- Volunteers
- 729 people
- Sponsor
- Orexigen Therapeutics, Inc
Obesity, Nutritional and Metabolic Diseases
A Study of the Safety of R256918 in Obese Patients
This study investigates the safety of 12 weeks of treatment with R256918, in obese patients (JNJ-16269110 and R256918 are different names for the same molecule).
- Conditions
- Obesity, Nutritional and Metabolic Diseases, Metabolic Diseases, Nutrition Disorders
- Trial name
- NCT01041677
- Testing
- R256918
- Where
- 3 sites in Finland, Netherlands and 1 more
- Volunteers
- 71 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Hypogonadism
Efficacy and Tolerability of Testogel/Nebido in Combination With Exercise and Diet in Hypogonadal Male Patients
With advancing age testosterone levels decline in men. Low testosterone levels plus certain symptoms are called "Late Onset Hypogonadism (LOH)". Adipose tissue may contribute to testosterone deficiency.
- Trial name
- NCT00847314
- Testing
- Testosterone Undeconate (Nebido-R, BAY86-5037)
- Where
- Germany
- Volunteers
- 30 people
- Sponsor
- Bayer
Central Abdominal Bulging
Evaluating the Safety and Efficacy of LIPO-202 for the Reduction of Central Abdominal Bulging Due to Subcutaneous Fat (AbCONTOUR2)
This is a multi-center, randomized, double-blinded, placebo-controlled study evaluating the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat in non-obese subjects.
- Trial name
- NCT02398188
- Testing
- LIPO-202
- Where
- 35 sites in United States
- Volunteers
- 793 people, healthy volunteers welcome
- Sponsor
- Evofem Inc.
Obesity
Feasibility Trial of ValenTx Endo Bypass System of the ValenTx Endo Bypass System in Obese Subjects
The purpose of this study is to provide initial clinical data to support the feasibility of use of the ValenTx Endo Bypass system in enhancing weight loss and co-morbidity resolution in morbidly obese subjects
- Trial name
- NCT01207830
- Testing
- Endo Bypass System
- Where
- Mexico
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- ValenTx, Inc.
Obesity
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Following screening, eligible subjects will be enrolled into a 6-week Low Calorie Diet (LCD) lead-in period. Subjects who lose at least 2% of their body weight at the end of the 6-week LCD lead-in period will be randomized to 1…
- Trial name
- NCT01235741
- Testing
- Pramlintide+Metreleptin
- Where
- 18 sites in United States
- Volunteers
- 213 people
- Sponsor
- AstraZeneca